Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034925.xml
Download PDF
Hamostaseologie 1987; 07(05): 115-119
DOI: 10.1055/s-0038-1660540
DOI: 10.1055/s-0038-1660540
Originalarbeit
Hämostaseologische Therapie mit Prostaglandinen aus pharmakologischer Sicht
Further Information
Publication History
Publication Date:
22 July 2018 (online)
-
LITERATUR
- 1 Aren C, Feddersen K, Radegran K. Effects of prostacyclin infusion on platelet activation and postoperative blood loss in coronary bypass. Ann Thorac Surg 1983; 36: 49-54.
- 2 Aren C, Feddersen K, Radegran K. Effects of prostacyclin infusion on platelets and hemodynamics in coronary bypass surgery. Thorac Cardiovasc Surg 1984; 32: 81-4.
- 3 Berglund U, von Scheck H, Wallentin L. Effects of ticlopidine on platelet function in men with stable angina pectoris. Thromb Haemost 1985; 54: 808-12.
- 4 Bunce I, Ward M, Solomon E, Cowen A. Platelet function in patients receiving enprostil. Am J Med 1986; 81: 85-8.
- 5 Bunting S, O’Grady J, Fabiani J N, Terrier E, Moncada S, Vane J R, Dubost C. Cardiopulmonary bypass in man: effects of prostacyclin. In: Clinical Pharmacology of Prostacyclin. Lewis P J, O’Grady J. (eds). New York: Raven Press; 1981: 181.
- 6 Cizmeci G. In vivo effects of defibrotide on platelet c-AMP and blood prostanoid levels. Haemostasis 1986; 16 (Suppl. 01) 31-5.
- 7 Coppe D, Sobel M, Seamans L, Levine F, Salzman E. Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981; 81: 274.
- 8 Crutchley D J, Conanan L B, Maynard J R. Stimulation of fibrinolytic activity in human skin fibroblasts by prostaglandins E1, E2 and I2 . J Pharmacol Exp Ther 1982; 222: 544-9.
- 9 Darius H, Hossmann V, Schrör K. Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. Klin Wochenschr 1986; 64: 545-51.
- 10 Davi G, Cannizzaro S, Giubilato A, Novo S, Mattina A, Strano A. Enhanced platelet sensitivity to prostacyclin after isosorbide-5-mononitrate in patients with stable angina pectoris. Z Kardiol 1986; 75 (Suppl. 03) 80-2.
- 11 Dembinska-Kiec A, Kostka-Trabka E, Zumbda A, Byrska-Danek A, Bieron K, Grodzinska L, Kedzior A, Zelazny T. Effect of prostacyclin (PGI2) on platelets and fibrinolytic activity in patients with arteriosclerosis obliterans. Pharmacol Res Commun 1982; 14: 485-98.
- 12 Dembinska-Kiec A, Zmuda A, Grodzinska L, Bieron K, Basista M, Kedzor A, Kostka-Trabka E, Telesz E, Zelazny T. Increased platelet activity after termination of prostacyclin infusion into man. Prostaglandins 1981; 21: 827-32.
- 13 Ditter H, Heinrich D, Matthias F R, Sellmann-Richter R, Wagner W L, Herlein F W. Effects of prostacyclin during cardiopulmonary bypass in men on plasma levels of beta-thromboglobulin, platelet factor 4, thromboxane B2, 6-keto-prostaglandin Flα and heparin. Thromb Res 1983; 32: 393-408.
- 14 Eika C. Inhibition of thrombin induced aggregation of human platelets by heparin. Scand J Haematol 1971; 08: 216-22.
- 15 Eldor A, Weksler B B. Heparin and dextrane sulfate antagonize PGI2 inhibition of platelet, aggregation. Thromb Res 1979; 16: 617-28.
- 16 Fisher C A, Reiser H J, Addonizzio P. Preliminary comparison of the effects of iloprost, prostacyclin (PGI2) and prostaglandin E1 on human platelet function. In: Prostacyclin and its Stable Analog Iloprost. Gryglewski R J, Stock G. (Eds). Berlin: Springer; 1987: 65-8.
- 17 Fitscha P, Kaliman J, Sinzinger H. Gamma-camera imaging after autologous human platelet labeling with 111In-oxine-sulfate: a key for assessing the efficacy of prostacyclin treatment in active atherosclerosis?. In: Prostaglandins and Other Eicosanoids in the Cardiovascular System. Schrör K. (Ed). Basel: Karger; 1985: 352-7.
- 18 Foegh M L, Alijani M R, Helfrich G B, Ramwell P W. Eicosanoids and organ transplantation. Ann Clin Res 1984; 16: 318-23.
- 19 Foegh M L, Rowles J R, Khirbadi B S, Ramwell P W. Allograft survival with iloprost. In: Prostacyclin and its Stable Analog Iloprost. Gryglewski R J, Stock G. (Eds). Berlin: Springer; 1987: 243-6.
- 20 George J N, Käser-Glanzmann R, Kallabora M, Liischer E F. Adenosine 3’5-cyclic monophosphate (cAMP) stimulation of active calcium transport by a membrane fraction from human platelets: a possible controlling mechanism of platelet function. Blood 1976; 48: 1007.
- 21 Gorman R R, Bunting S, Miller O V. Modulation of human platelet adenylate cyclase by prostacyclin (PGX).. Prostaglandins 1977; 13: 377.
- 22 Gimson A, Braude S, Mellon P, Canalese J, Williams R, Weston M. Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet 1982; I: 173.
- 23 Gimson A, Braude S, Mellon P, Canalese J, Williams R. Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet 1982; II: 681-3.
- 24 Gryglewski R J, Szczeklik A. Prostacyclin in vascular pathology-therapeutic possibilities. Ann Clin Res 1984; 16: 253-61.
- 25 Heinrich D, Schleussner E, Wagner W L, Sellmann-Richter R, Hehrlein F W. Prostacyclin in aortocoronary bypass surgery: a double-blind, placebo-controlled study. Thromb Res 1983; 32: 409-26.
- 26 Higgs G A, Moncada S, Vane J R. Prostacyclin (PGI2) inhibits the formation of platelet thrombin induced by adenosine diphosphate (ADP) in vivo. Br J Pharmacol 1977; 61: 137P
- 27 Kloeze J. Relationship between chemical structure and platelet aggregation activity of prostaglandins. Biochim Biophys Acta 1969; 187: 285.
- 28 Kloeze J. Influence of prostaglandins on platelet adhesiveness and platelet aggregation. In: Prostaglandins. Proceedings of the Second Nobel Symposium. Bergström S, Samuelsson B. (Eds). Stockholm: Almqvist und Wiksell; 1966: 241.
- 29 Koshal A, Krausz M M, Utsonomiya T, Hechtman H B, Collins J J, Cohn L H. Preservation of platelets and their function in prolonged cardiopulmonary bypass using prostacyclin. Circulation 1981; 64: 44.
- 30 Leithner C, Sinzinger H, Pohanka E, Schwarz M, Syre G. 111Indiummarkierte Thrombozyten in der Diagnostik von akuten Nierentransplantatabstoßungen und zur Observierung der Therapie von Abstoßungsreaktionen mit Prostacyclin. Wien Klin Wochenschr 1984; 96: 112-7.
- 31 Leithner C, Sinzinger H, Schwarz M. Treatment of chronic kidney transplant rejection with prostacyclin – reduction of platelet deposition in the transplant; prolongation of platelet survival and improvement of transplant function. Prostaglandins 1981; 22: 783-8.
- 32 Lewis P J, Dollery C T. Clinical pharmacology and potential of prostacyclin. Br Med Bull 1983; 39: 281-4.
- 33 Lewis R, Schoelkens B A, Beck G. Biological activities of 6-keto-prostaglandin E1 . Prostaglandins Leukotrienes Med 1984; 16: 303-24.
- 34 Löbel P, Schrör K. Selective stimulation of coronary vascular PGI2 but not of platelet thromboxane formation by defibrotide in the platelet perfused heart. Naunyn-Schmiedeberg’s Arch Pharmacol 1985; 331: 125-30.
- 35 Longmore D B. Experience with prostacyclin in cardiopulmonary bypass in dog and man. Philos Trans R. Soc Lond (Biol) 1981; 294: 399-412.
- 36 Longmore D, Bennet J, Hoyle P, Smith M, Gregory A, Osivand T, Jones W. Prostacyclin administration during cardiopulmonary bypass in man. Lancet 1981; I: 800-3.
- 37 MacDermot J. Desensitization of prostacyclin responsiveness in platelets. Apparent differences in the mechanism in vitro or in vivo. Biochem Pharmacol 1986; 35: 2645-9.
- 38 Machin S J, Yardumain D A, O’Flynn K, Linch D C. Laboratory investigations of potential hepariniloprost interactions. In: Prostacyclin and its Stable Analog Iloprost. Gryglewski R J, Stock G. (Eds). Berlin: Springer; 1987: 69-79.
- 39 Malpass T W, Hanson S R, Savage B, Hessel E A, Harker L A. Prevention of aquired transient defect in platelet plug formation by infused prostacyclin. Blood 1981; 57: 736.
- 40 Mitchell J R. Prostacyclin – powerful, yes: but is it useful?. Br Med J 1983; 287: 1824-6.
- 41 Noback C, Tinker J, Kaye M, Holocom G, Pluth J. Prostacyclin : a potent vasodilator during anaesthesia and cardiac surgery in man. Circulation 1983; 62 (Suppl III): 111-322.
- 42 Preston F E. Aspirin, prostaglandins, and peripheral gangrene. Am J Med 1983; 74: 55-60.
- 43 Radegran K, Papaconstantinou C. Prostacyclin infusion during cardiopulmonary bypass in man. Thromb Res 1980; 19: 267-70.
- 44 Radegran K, Aren C, Teger-Nilsson A C. Prostacyclin infusion during extracorporeal circulation for coronary bypass. J Thorac Cardiovasc Surg 1982; 83: 205-122.
- 45 Reches A, Eldor A, Salomon Y. Heparin inhibits PGE! sensitive adenylate cyclase and antagonizes PGEi anti aggregating effect in human platelets. J Lab Clin Med 1979; 93: 638.
- 46 Rylance P B, Gordge M P, Ireland H, Lane D A, Weston M J. Haemodialysis with prostacyclin (Epoprostenol) alone. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985; 21: 281-6.
- 47 Salzman E W, Merill E W. Interaction of blood with artificial surfaces. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman R W, Hirsh J, Salzmann E W. (Eds). Philadelphia – Toronto: Lippincott; 1982: 931.
- 48 Schrör K, Ahland B, Darius H, Weiss P. Stimulation of vascular PGI2 by organic nitrates and its significance for the antianginal effect. Scand J Clin Lab Invest 1984; (Suppl) 173: 33-40.
- 49 Schrör K. Kardiovaskuläre Wirkung von Prostaglandin E1 (PGE1)-Mechanismen und ihre mögliche klinische Bedeutung. In: Prostaglandin E1. Therapie der arteriellen Verschlußkrankheit. Schrey A. (Hrsg). München: Wolf; 1985: S15-32.
- 50 Schrör K, Hecker G. Potent inhibition of superoxide anion generation by PGE1 and the PGE1 analog OP-1206 in human PMN’s – unrelated to its antiplatelet PGI2-like activity. Vasa 1987; (Suppl. 17) 11-6.
- 51 Sinzinger H, Fitscha P. Influence of prostaglandin E1 on in-vivo accumulation of radiolabelled platelets and LDL on human arteries. Vasa 1987; (Suppl. 17) 5-10.
- 52 Sinzinger H, Reiter S. The intrainfusion platelet rebound during and following PGE1infusion is faster and more intensive than that with PGI2 . Prostaglandins Leukotrienes Med 1984; 13: 281-8.
- 53 Sinzinger H, Matejka M, Steurer G, Kaliman J, Ettl K. The interaction between the platelet- derived growth factor (PDGF) and prostaglandin (PG)I2 is important for atherogenesis. Abstr 6th International Conference on Prostaglandins 1986; 14
- 54 Sinzinger H, Kaliman J, Widhalm K, Pachinger O, Probst P. Value of platelet sensitivity to antiaggregatory prostaglandins (PGE2, PGE1 PGD2) in 50 patients with myocardial infarction and young age. Prostaglandins Med 1981; 07: 125-32.
- 55 Sinzinger H, Horsch A K, Silberbauer K. The behaviour of various platelet function tests during long-term prostacyclin infusion in patients with peripheral vascular disease. Thromb Haemost 1983; 50: 885.
- 56 Sinzinger H, Silberbauer K, Horsch A K, Gall A. Decreased sensitivity of human platelets to PGI2 during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease – a rebound phenomenon. Prostaglandins 1981; 21: 49-51.
- 57 Sinzinger H, Silberbauer K, Feigl W, Wagner O, Winter M, Auerswald W. Prostacyclin activity is diminished in different types of morphologically controlled human atherosclerotic lesions. Thromb Haemostas 1979; 42: 803-4.
- 58 Smith D L, Willis A L, Nguyen N, Dave S, Yih R, Nakamura G. Antiatherosclerotic properties of prostacyclins on release of mitogens from platelets and endothelial cells. Excerpta Medica Intern Cong Ser 1986; 696: 453-6.
- 59 Strom T B, Carpenter C B. Prostaglandin as an effective antirejection therapy in rat renal allograft recipients. Transplantation 1983; 35: 279-81.
- 60 Stürzebecher C-S, Losert W. Effects of iloprost on platelet activation in vitro. In: Prostacyclin and its Stable Analog Iloprost. Gryglewski R J, Stock G. (Eds). Berlin: Springer; 1987: 39-46.
- 61 Turney J H, Fewell M R, Williams L C, Parsons V, Westo M J. Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet 1980; I: 219.
- 62 van den Dungen J J, Karliczek G F, Brenken U, van der Heide J N, Wildevuur C R. The effect of prostaglandin Ej in patients undergoing clinical cardiopulmonary bypass. Ann Thorac Surg 1983; 35: 406-14.
- 63 Vane J R. Prostacyclin in the cardiovascular system in health and disease. In: Prostaglandins and Other Eicosanoids in the Cardiovascular System. Schrör K. (Ed). Basel: Karger; 1985: 7-38.
- 64 Walker I D, Davidson J F, Faichney A, Wheatley D J, Davidson K G. A double blind study of prostacyclin in cardiopulmonary bypass surgery. Br J Haematol 1981; 49: 415-23.
- 65 Weeks J R, Chandra NSekar, Ducharme D W. Relative activity of prostaglandins E1, A1, E2 and A2 on lipolysis, platelet aggregation, smooth muscle and the cardiovascular system. J Pharm Pharmacol 1969; 21: 103.
- 66 Yardumian D A, Mackie I J, Brennan E C, Bull H, Machin S J. Platelet function studies during and after infusions of ZK 36374, a stable prostacyclin analogue, to healthy volunteers. Haemost 1986; 16: 20-6.
- 67 Zusman R, Rubin R, Cato A, Cochetto D, Crow J, Tolkoff-Rubin N. Haemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 1981; 304: 934-9.